BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36207812)

  • 21. Usefulness of immunohistochemistry to distinguish between secretory carcinoma and acinic cell carcinoma in the salivary gland.
    Hamamoto Y; Harada H; Kohara M; Honma K; Nakatsuka SI; Morii E
    Med Mol Morphol; 2021 Mar; 54(1):23-30. PubMed ID: 32488412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
    Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
    Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
    Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
    Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
    Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of MUC4 in the diagnosis of secretory carcinoma of salivary glands.
    Fatima S; Ahmed A; Suleman S; Din NU
    Ann Diagn Pathol; 2023 Dec; 67():152220. PubMed ID: 37924657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma.
    Chiosea SI; Griffith C; Assaad A; Seethala RR
    Am J Surg Pathol; 2012 Mar; 36(3):343-50. PubMed ID: 22301503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers.
    Kawahara A; Taira T; Abe H; Takase Y; Kurita T; Sadashima E; Hattori S; Imamura I; Matsumoto S; Fujisaki H; Sueyoshi K; Akiba J; Kage M
    Cancer Cytopathol; 2015 Oct; 123(10):603-11. PubMed ID: 26252941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
    Katabi N
    Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
    Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
    BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Approaches for Salivary Gland Tumors with Secretory and Microcystic Features.
    Woo HY; Choi EC; Yoon SO
    Head Neck Pathol; 2018 Jun; 12(2):237-243. PubMed ID: 29139086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
    Skálová A; Vanecek T; Sima R; Laco J; Weinreb I; Perez-Ordonez B; Starek I; Geierova M; Simpson RH; Passador-Santos F; Ryska A; Leivo I; Kinkor Z; Michal M
    Am J Surg Pathol; 2010 May; 34(5):599-608. PubMed ID: 20410810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland].
    Cheng K; Wang X; Wei X; Ma J; Xia QY; Shi QL; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1142-1146. PubMed ID: 33152819
    [No Abstract]   [Full Text] [Related]  

  • 33. Secretory carcinoma of the sinonasal cavity and pharynx: A retrospective analysis of four cases and literature review.
    Yue C; Zhao X; Ma D; Piao Y
    Ann Diagn Pathol; 2022 Dec; 61():152052. PubMed ID: 36270241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas.
    Sams RN; Gnepp DR
    Head Neck Pathol; 2013 Mar; 7(1):64-8. PubMed ID: 23054955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic features of mammary analogue secretory carcinoma of salivary glands].
    Zhang XP; Ni H; Wang X; Chen H; Shi SS; Yu B; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):34-37. PubMed ID: 28072974
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical characteristics of acinic cell carcinoma and secretory carcinoma of the parotid gland.
    Terada T; Kawata R; Noro K; Higashino M; Nishikawa S; Haginomori SI; Kurisu Y; Kuwabara H; Hirose Y
    Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3461-3466. PubMed ID: 31440815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NR4A3 Immunostain Is a Highly Sensitive and Specific Marker for Acinic Cell Carcinoma in Cytologic and Surgical Specimens.
    Viswanathan K; Beg S; He B; Zhang T; Cantley R; Lubin DJ; Shi Q; Maleki Z; Asiry S; Rao R; Katabi N; Nakaguro M; Faquin WC; Sadow PM; Siddiqui MT; Scognamiglio T
    Am J Clin Pathol; 2022 Jan; 157(1):98-108. PubMed ID: 34508546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.
    Haller F; Skálová A; Ihrler S; Märkl B; Bieg M; Moskalev EA; Erber R; Blank S; Winkelmann C; Hebele S; Baněčková M; Wiemann S; Müller S; Zenk J; Eils R; Iro H; Hartmann A; Agaimy A
    Am J Surg Pathol; 2019 Sep; 43(9):1264-1272. PubMed ID: 31094928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and treatment of secretory carcinoma arising from the oral minor salivary gland: Two case reports.
    Ogawa M; Yokoo S; Yamaguchi T; Suzuki K; Seki-Soda M; Shimizu T; Kurihara J; Makiguchi T
    Medicine (Baltimore); 2021 Dec; 100(51):e28390. PubMed ID: 34941172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
    Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.